F
Fong Seng Lim
Researcher at National University of Singapore
Publications - 2
Citations - 122
Fong Seng Lim is an academic researcher from National University of Singapore. The author has contributed to research in topics: Vaccination & Respiratory tract infections. The author has an hindex of 2, co-authored 2 publications receiving 100 citations. Previous affiliations of Fong Seng Lim include National Healthcare Group.
Papers
More filters
Journal ArticleDOI
Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample.
Sylvia Taylor,Pio Lopez,Lily Yin Weckx,Charissa Borja-Tabora,Rolando Ulloa-Gutierrez,Eduardo Lazcano-Ponce,Angkool Kerdpanich,Miguel Angel Rodriguez Weber,Abiel Mascareñas de los Santos,Juan Carlos Tinoco,Marco Aurélio Palazzi Sáfadi,Fong Seng Lim,Marcela Hernandez-de Mezerville,Idis Faingezicht,Aurelio Cruz-Valdez,Yang Feng,Ping Li,Serge Durviaux,Gerco Haars,Sumita Roy-Ghanta,David W. Vaughn,Terry Nolan +21 more
TL;DR: Active surveillance of healthy children provided evidence of respiratory illness burden associated with several viruses, with a substantial burden in older children.
Journal ArticleDOI
Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
Terry Nolan,Sumita Roy-Ghanta,May Montellano,Lily Yin Weckx,Rolando Ulloa-Gutierrez,Eduardo Lazcano-Ponce,Angkool Kerdpanich,Marco Aurélio Palazzi Sáfadi,Aurelio Cruz-Valdez,Sandra Litao,Fong Seng Lim,Abiel Mascareñas de los Santos,Miguel Angel Rodriguez Weber,Juan Carlos Tinoco,Marcela Hernandez-de Mezerville,Idis Faingezicht,Pensri Kosuwon,Pio Lopez,Charissa Borja-Tabora,Ping Li,Serge Durviaux,Louis Fries,Gary Dubin,Thomas Breuer,Bruce L. Innis,David W. Vaughn +25 more
TL;DR: The 4–8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and clinically important prevention of A(H1N1)pdm09 infection, compared with nonadjuvanted vaccine, with no observed increase in medically attended or serious adverse events, and these data support the use of adjuvanting influenza vaccines during influenza pandemics.